Compare Stocks
Compare up to four stocks to (AVTX) by adding the symbol or company name.
AVTX
Compare up to three stocks to AVTX by adding the symbol or company name. | Add Stock | Add Stock | Add Stock |
As of May 15, 2024 | AVTX Avalo Therapeutics, Inc. | -- | -- | -- |
---|---|---|---|---|
Market Value | Market Value 11.19M | Market Value -- | Market Value -- | Market Value -- |
Enterprise Value | EV 4.31M | EV -- | EV -- | EV -- |
Price to Earnings | Price to Earnings -- | Price to Earnings -- | Price to Earnings -- | Price to Earnings -- |
Diluted Earnings Per Share | Diluted EPS TTM -114.00 | Diluted EPS TTM -- | Diluted EPS TTM -- | Diluted EPS TTM -- |
Forward Dividend & Yield | Fwd Div Yld -- | Fwd Div Yld -- | Fwd Div Yld -- | Fwd Div Yld -- |
Sector | Sector Healthcare | Sector -- | Sector -- | Sector -- |
Industry | Industry Biotechnology | Industry -- | Industry -- | Industry -- |
CEO | CEO Dr. Garry A. Neil M.D. | CEO -- | CEO -- | CEO -- |
As of May 15, 2024 | AVTX Avalo Therapeutics, Inc. | -- | -- | -- |
---|---|---|---|---|
1 Week | 1 Week -21.54% | 1 Week -- | 1 Week -- | 1 Week -- |
3 Months | 3 Months 120.37% | 3 Months -- | 3 Months -- | 3 Months -- |
YTD | YTD 16.48% | YTD -- | YTD -- | YTD -- |
1 Year | 1 Year -98.20% | 1 Year -- | 1 Year -- | 1 Year -- |
As of May 15, 2024 | AVTX Avalo Therapeutics, Inc. | -- | -- | -- |
---|---|---|---|---|
Revenue | Revenue 1.92M | Revenue -- | Revenue -- | Revenue -- |
Operating Expenses | Operating Expenses 24.08M | Operating Expenses -- | Operating Expenses -- | Operating Expenses -- |
Operating Income | Operating Income -23.44M | Operating Income -- | Operating Income -- | Operating Income -- |
Revenue Growth YoY | Rev Gr 1Y -36.27% | Rev Gr 1Y -- | Rev Gr 1Y -- | Rev Gr 1Y -- |
Gross Profit | Gross Profit 640.00k | Gross Profit -- | Gross Profit -- | Gross Profit -- |
As of May 15, 2024 | AVTX Avalo Therapeutics, Inc. | -- | -- | -- |
---|---|---|---|---|
Inventory | Inventory -- | Inventory -- | Inventory -- | Inventory -- |
Account Receivables Turnover | A/R Turnover 28.29 | A/R Turnover -- | A/R Turnover -- | A/R Turnover -- |
As of May 15, 2024 | AVTX Avalo Therapeutics, Inc. | -- | -- | -- |
---|---|---|---|---|
Cash Flow from Operations | CF from Ops -30.68M | CF from Ops -- | CF from Ops -- | CF from Ops -- |
Capital Expenditures | CapEx -95.00k | CapEx -- | CapEx -- | CapEx -- |
Cash from Investing Activities | CFI -133.00k | CFI -- | CFI -- | CFI -- |
Free Cash Flow | Free Cash Flow -30.68M | Free Cash Flow -- | Free Cash Flow -- | Free Cash Flow -- |
As of May 15, 2024 | AVTX Avalo Therapeutics, Inc. | -- | -- | -- |
---|---|---|---|---|
Price to Earnings Per Share | P/E -- | P/E -- | P/E -- | P/E -- |
Forward Price to Earnings Per Share | Fwd P/E -- | Fwd P/E -- | Fwd P/E -- | Fwd P/E -- |
Price to Free Cash Flow Per Share | P/FCF -- | P/FCF -- | P/FCF -- | P/FCF -- |
Price to Book Value Per Share | P/BV 1.53 | P/BV -- | P/BV -- | P/BV -- |
Price to Sales Ratio | P/S 1.56 | P/S -- | P/S -- | P/S -- |
EV/EBITDA | EV/EBITDA -0.19 | EV/EBITDA -- | EV/EBITDA -- | EV/EBITDA -- |
As of May 15, 2024 | AVTX Avalo Therapeutics, Inc. | -- | -- | -- |
---|---|---|---|---|
Operating Margin | Oper. Margin -1,218.50% | Oper. Margin -- | Oper. Margin -- | Oper. Margin -- |
Gross Margin | Gross Margin 33.26% | Gross Margin -- | Gross Margin -- | Gross Margin -- |
Profit Margin | Profit Margin -1,639.50% | Profit Margin -- | Profit Margin -- | Profit Margin -- |
As of May 15, 2024 | AVTX Avalo Therapeutics, Inc. | -- | -- | -- |
---|---|---|---|---|
Basic Earnings Per Share | EPS -114.00 | EPS -- | EPS -- | EPS -- |
EPS 1Yr Growth | EPS 1Yr Growth 0.00% | EPS 1Yr Growth -- | EPS 1Yr Growth -- | EPS 1Yr Growth -- |
As of May 15, 2024 | AVTX Avalo Therapeutics, Inc. | -- | -- | -- |
---|---|---|---|---|
Return on Assets | Return on Assets -116.06% | Return on Assets -- | Return on Assets -- | Return on Assets -- |
Return on Capital | Return on Capital -364.27% | Return on Capital -- | Return on Capital -- | Return on Capital -- |
As of May 15, 2024 | AVTX Avalo Therapeutics, Inc. | -- | -- | -- |
---|---|---|---|---|
Institutional Ownership % | Inst. Own. % 4.95% | Inst. Own. % -- | Inst. Own. % -- | Inst. Own. % -- |